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Abstract 
 
Introduction 
Around 5-10% of hypothyroid patients continue to experience profound and 
sometimes disabling symptoms, including fatigue, depression and impaired 
cognition, in spite of being adequately replaced biochemically.  
The use of liothyronine and natural desiccated thyroid extract is controversial for 
reasons of costs, a lack of evidence of additional benefit over levothyroxine alone, 
and potential safety concerns.  
Methods 
We recruited self-selecting patients with the help of a national thyroid charity who 
reported to be clinically resistant to levothyroxine despite being biochemically 
euthyroid. They were invited to complete an on-line, validated multi-attribute health 
utility instrument, the EuroQol EQ-5D-5L questionnaire and accompanying EQ-VAS 
(visual analogue scale). EQ-5D-5L index values (utilities, a preference-weighted 
measure of patients’ health valuation) were estimated based on the EQ-5D-5L cross 
walk value set for the UK.  
Results 
Responses were available from 54 people. Mean (SD, minimum, maximum) EQ-5D-
5L utility was 0.53 (0.23, -0.00, 0.84); and EQ-VAS was 49.3 (17.2, 5.0, 90.0). 44/54 
(81%) individuals reported having moderate problems in at least one attribute, most 
often their ability to perform usual activities, and anxiety or depression; 24/54 (44%) 
reported severe problems; and 6/54 (11%) reported extreme problems. 
Conclusion 
Reported health utilities in these individuals are comparable to those reported by 
patients with lung cancer, or acute cerebrovascular disease and rank in the bottom 
decile of 100 chronic diseases. 
A lack of proven effective treatment and a large unmet need indicates that now is the 
right time for a definitive clinical trial to address this important area of uncertainty. 
 
  
What is known about this topic? 
 
• A significant minority of patients with hypothyroidism remain symptomatic despite 
being adherent to, and biochemically controlled with levothyroxine. 
• The NHS in the UK prohibits the routine use of liothyronine and natural 
desiccated thyroid extract for reasons of cost, a lack of evidence of additional 
benefit over levothyroxine alone, and potential safety concerns. 
• There are no clinical trials of liothyronine and natural desiccated thyroid extract in 
this patient sub-group.  
 
What does this article add? 
 
• Reported health utilities in these individuals are comparable to those reported by 
patients with lung cancer, or acute cerebrovascular disease and would rank in the 
bottom decile of 100 chronic diseases. 
• Testing whether alternatives to levothyroxine alone are clinically and cost 
effective is now regarded as a research priority. 
1. Introduction 
 
Primary hypothyroidism affects about 3% of the general population (5.1% women 
and 0.9% men) [1]. The majority of people are treated adequately with levothyroxine 
(L-thyroxine). However about 5-10% of hypothyroid patients (representing between 
75,000 and 150,000 adults in the UK) continue to experience profound and 
sometimes disabling symptoms, such as fatigue, depression and impaired cognition, 
in spite of being adequately replaced biochemically [2].  
Supplemental liothyronine (L-tri-iodothyronine) plus levothyroxine was originally the 
treatment of choice when synthetic thyroid hormones first replaced animal thyroid 
extracts. However, with its more favourable posology and no evidence for any 
additional benefit of liothyronine, levothyroxine monotherapy became the treatment 
of choice. Nevertheless, supplemental liothyronine remains a treatment option which 
has been prescribed by some general practitioners and by endocrinologists across 
the UK for a long time. A few endocrinologists prescribe natural desiccated thyroid 
extract (NDTE) with anecdotal evidence of benefit, but which is unlicensed in the UK. 
Clinical guidelines that apply in the UK only support the use of levothyroxine, and 
advise that liothyronine should only to be used in exceptional cases [3-5], principally 
owing to its high cost. Together, liothyronine and NDTE formulations cost the NHS 
£35m in 2016. The restriction of liothyronine and NDTE as treatment options led to 
great consternation among patients, with around 20,000 people signing a British 
Thyroid Foundation petition for continued access. In response to its consultation on 
medicines which should not be routinely prescribed in primary care, NHS England 
received a significant feedback from patients and organisational bodies, which 
highlighted that “A treatment that leads to improvements in the health-related quality 
of life of patients with symptoms of hypothyroidism would represent a significant 
unmet need”. The draft NICE guidance lists, as the first research priority, “What is the 
clinical and cost effectiveness of levothyroxine and liothyronine combination therapy 
compared with levothyroxine alone for people with hypothyroidism whose symptoms 
have not responded sufficiently to levothyroxine alone?”. 
2. Review of existing evidence 
Thirteen trials using combined liothyronine plus levothyroxine therapy have been 
reported; 7 cross-over [6-12] and 6 parallel in design [13-18]. Most are underpowered 
with sample sizes of 10 to 71 [6-10, 14-16].  Although some studies have shown a 
beneficial effect, such as patient preference for combination therapy or an improved 
metabolic profile, patients on combination therapy generally do not have improved 
outcomes compared with those on levothyroxine monotherapy. Among the larger 
trials, Walsh et al [11] (n=110) found no difference in patient wellbeing, quality of life 
(Short Form-36, General Health Questionnaire (GHQ)-28, Thyroid Symptom 
Questionnaire) or cognitive function. Appelhof et al [13] (n=140) reported that for the 
primary outcome, patients preferred liothyronine plus levothyroxine to levothyroxine 
alone over 15 weeks but there were no differences in secondary outcomes. In the 
largest trial [17], which was double-blind and randomised 697 patients, the difference 
between liothyronine plus levothyroxine and levothyroxine alone in the co-primary 
outcomes at 3 months was 0.47 points (95%CI, -0.26, +1.12) for the GHQ-12 score; 
and 0.61 (95%CI, 0.42, 0.90) in the odds ratio for patients scoring ≥3 in GHQ-12. 
There was a significant difference in Hospital Anxiety and Depression Scale (HADS) 
anxiety score (odds ratio, 0.55; 95% CI, 0.32, 0.95) but not in other secondary 
patient-reported outcome measures. Differences in GHQ caseness and HADS 
anxiety were not apparent after 12 months. A recent pharmacoepidemiological study 
did not identify any additional risk of atrial fibrillation, cardiovascular disease or 
fractures with liothyronine [19]. 
Most studies of NDTE have been uncontrolled and open-label, and compared NDTE 
with levothyroxine, not in terms of efficacy and safety but in terms of comparative 
potency, onset and duration of action, and effects on serum lipids [20-23]. There is 
only one randomised, double-blind, cross-over trial comparing NDTE with 
levothyroxine [24], but in an unselected population of 70 people with primary 
hypothyroidism. Following 12 weeks (period 1) and 16 weeks (period 2) of treatment, 
there were no differences in symptom scores, general health questionnaires or 
neuropsychological testing between treatment groups. No study patient had a thyroid 
stimulating hormone level outside of the reference range.  No adverse events were 
reported with any of the treatments; both were tolerated equally well.   
3. What we did 
We aimed to estimate the health utility of patients with clinically resistant 
hypothyroidism in order to compare with other chronic diseases, and to estimate the 
standard deviation of utility values for future trial sample size calculations. 
We recruited self-selecting patients who reported to be clinically resistant to 
levothyroxine despite being biochemically euthyroid, with the help of a national 
thyroid charity. Patients were invited to complete an on-line, validated multi-attribute 
health utility instrument, the EuroQol EQ-5D-5L questionnaire and accompanying 
EQ-VAS (visual analogue scale). The EQ-5D-5L questionnaire asks about 5 
dimensions of health (mobility, self-care, usual activities, pain/discomfort and 
anxiety/depression). Each dimension has 5 levels: no problems, slight problems, 
moderate problems, severe problems and extreme problems. EQ-5D-5L profiles 
were converted to EQ-5D-5L index values (utilities, a preference-weighted measure 
of patients’ health valuation) based on the EQ-5D-5L cross walk value set for the UK.  
The EQ VAS records the patient’s self-rated health on a vertical visual analogue 
scale, where the endpoints are labelled ‘The best health you can imagine’ and ‘The 
worst health you can imagine’. The VAS was used as a quantitative measure of 
health outcome that reflect the patient’s own judgement. 
4. What we found 
Responses were available from 54 people. Mean (SD, minimum, maximum) EQ-5D-
5L utility was 0.53 (0.23, -0.00, 0.84). 44/54 (81%) individuals reported having 
moderate problems (level scores ≥3) in at least one attribute, most often their ability 
to perform usual activities, and anxiety or depression; 24/54 (44%) reported severe 
problems (level scores ≥4); and 6/54 (11%) reported extreme problems (level 5) 
(Figure 1). 
Reported health utilities in these individuals were comparable to those reported by 
patients with lung cancer, or acute cerebrovascular disease and would rank in the 
bottom decile of 100 chronic diseases. 
The mean (SD, minimum, maximum) EQ-VAS score was 49.3 (17.2, 5.0, 90.0). 
5. Why is a further trial important? 
Existing trial evidence is insufficient in several respects. Principally and most 
importantly, the trials did not recruit patients who did not feel significantly better on 
levothyroxine, and so failed to identify the actual subgroup that could benefit from 
liothyronine or NDTE. There is also improved understanding of the pharmacology of 
levothyroxine resistance. L-tri-iodothyronine is the endogenous thyroid hormone, 
converted from L-thyroxine by de-iodination.  Polymorphisms in the genetic coding of 
the deiodinase-2 enzyme may reduce L-tri-iodothyronine levels in many tissues, 
including the brain [25]. This may represent a pharmacogenetic component to non-
response to levothyroxine. 
Of direct relevance to this letter is that NICE draft guidance [26] has noted the value 
of a randomised control trial, to assess combination therapy in patients how remain 
symptomatic in spite of apparently adequate levothyroxine replacement. We suggest 
that it is now the right time to determine whether the alternatives to levothyroxine 
alone result in any benefit to patients who do not achieve adequate symptom 
resolution with this treatment. Results would also inform policy worldwide. 
6. Conclusion 
 
As the first assessment of EQ-5D-5L utilities in a patient group with resistant 
hypothyroidism, our findings provide a basis for powering a trial of alternative 
treatment options to levothyroxine. Reported health utilities in these individuals are 
comparable to those reported by patients with lung cancer, or acute cerebrovascular 
disease and would rank in the bottom decile of 100 chronic diseases. 
 
The management of patients who are biochemically well-controlled with 
levothyroxine but who remain symptomatic is challenging and often unsatisfactory for 
patient and clinician alike. The controversy and uncertainty surrounding the benefits 
and cost-effectiveness of supplemental liothyronine and NDTE are well recognised. 
Liothyronine is clinically effective but is not considered to be cost-effective because 
of relentless price inflation, although there is a lack of economic evidence.  
A robust evaluation of the clinical and cost-effectiveness of treatment options is 
necessary to determine whether any additional benefits of alternatives to 
levothyroxine justify the additional cost in patients who are seemingly resistant to 
conventional therapy with levothyroxine alone. This proposal has recently been 
supported by the NICE draft guidance for thyroid management [26].  
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Figure 1. Distribution of responses to each dimension of the EQ-5D-5L 
 
